The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000821392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
18/06/2026
Date registered
Help: Date registered
8/07/2026
Date last updated
Help: Date last updated
8/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
8/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Trialling a New Multianalyte Sensor for Continuous Monitoring of Ketone, Lactate, Glucose, and Oxygen in Intensive Care Patients
Scientific title
Clinical Feasibility of Using a Novel Multianalyte Sensor for Continuous Monitoring of Ketone, Lactate, Glucose, and Oxygen in Intensive Care Patients
Additional trial identifiers [1] 317608 0
Nil
Universal Trial Number (UTN)
Trial acronym
KeLOG-ICU
Related trial records

Health condition
Health condition(s) studied:
Diabetic ketoacidosis 342386 0
Type 1 diabetes 342387 0
Hypoxemic respiratory failure 342388 0
Circulatory compromise 342389 0
Type 2 diabetes 342390 0
Condition category
Condition code
Metabolic and Endocrine 338512 338512 0 0
Diabetes
Respiratory 338513 338513 0 0
Other respiratory disorders / diseases
Cardiovascular 338514 338514 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Single-site, blinded study, evaluating glucose, ketone, lactate and oxygen profiles using the PercuSense Atlas Health Multi-Analyte Sensor (MAS). All participants will be recruited through ICU. Three cohorts will be enrolled. Arm 1 includes adults admitted with diabetes who meet the clinical criteria of diabetic ketoacidosis (DKA). Arm 2 includes adults with hypoxemic respiratory failure. Arm 3 includes adults with circulatory compromise. Following consent, a blinded/masked study MAS will be inserted using the device applicator into the upper arm by a study team member. The MAS will be worn throughout the inpatient admission to collect glucose, ketone, lactate and oxygen data. In addition, the commercially available Abbott FreeStyle Libre 2 Plus continuous glucose monitor (CGM) will be inserted into the contralateral arm. The sensors will be worn for up to three days as an inpatient in ICU. After three days or at the time of discharge the study MAS and Libre CGM sensors will be removed by a study team member. If the participant remains in ICU for more than six days, the insertion of a second device will be considered as determined by the study doctor and the Libre CGM will remain in place until the second MAS is removed. Intervention fidelity will be assessed using data uploaded from the MAS device throughout the participant's ICU stay.
The three cohorts in this study were developed to ensure that we had a sufficient range of readings pertinent to any given analyte. Each condition would provide significant variation specific parameters measured (eg respiratory failure would ensure readings in the hypoxic range; DKA would ensure elevated ketone readings etc) Therefore the primary analysis will be for data provided by the group as a whole.
Intervention code [1] 334433 0
Treatment: Devices
Description of the comparator or control
All participants will be transferred to the investigational device the PercuSense Atlas Health Multi-Analyte Sensor (MAS). The MAS will be used as a comparator in this study comparing outcomes to routine clinical care.

Routine clinical care in ICU involves invasive monitoring of analytes (oxygen, ketone, glucose, and lactate) through frequent venous or arterial blood samples. The frequency of blood sampling depends on the clinical state of the patients (ranging from hourly for critically ill patients to every 4-6 hours for more stable patients).
Control group
Active

Outcomes
Primary outcome [1] 345798 0
Duration (hours) of sensor function according to individual device (time to failure of sensing of any analyte on an individual device)
Timepoint [1] 345798 0
From time of ICU admission until discharge from hospital
Secondary outcome [1] 463338 0
Duration (hours) of sensor function according to individual analyte (each of the four analytes per sensor will be analysed separately).
Timepoint [1] 463338 0
From time of ICU admission until discharge from hospital
Secondary outcome [2] 463339 0
Sensor accuracy (mean absolute difference [MAD] / mean absolute relative difference [MARD]) for glucose will be determined by comparisons to venous blood glucose samples collected as part of routine clinical care in ICU and Libre2 continuous glucose monitor (CGM) glucose readings
Timepoint [2] 463339 0
From time of ICU admission until discharge from hospital
Secondary outcome [3] 463340 0
Impact of potential interfering substances (e.g. paracetamol) on sensor accuracy, with exploratory analyses of additional substances identified during the study.
Timepoint [3] 463340 0
From time of ICU admission until discharge from hospital
Secondary outcome [4] 463957 0
Sensor accuracy (MAD/ MARD) for lactate will be determined by comparisons to blood lactate measurements collected as part of routine clinical care in ICU
Timepoint [4] 463957 0
From time of ICU admission until discharge from hospital
Secondary outcome [5] 463958 0
Sensor accuracy (MAD/ MARD) for ketones will be determined by comparisons to blood ketone measurements collected as part of routine clinical care in ICU
Timepoint [5] 463958 0
From time of ICU admission until discharge from hospital
Secondary outcome [6] 463959 0
Sensor accuracy (MAD/ MARD) for oxygen will be determined by comparisons to arterial, venous and transcutaneous oxygen saturation measurements collected as part of routine clinical care in ICU
Timepoint [6] 463959 0
From time of ICU admission until discharge from hospital

Eligibility
Key inclusion criteria
Cohort 1:
• Men and non-pregnant women
• Aged 18 years of age and over
• Clinically diagnosed with T1D or T2D
• Meet the criteria for DKA
• Admitted to hospital as an inpatient into ICU

Cohort 2:
• Men and non-pregnant women
• Aged 18 years of age and over
• Clinically diagnosed with hypoxaemic respiratory failure
• Admitted to hospital as an inpatient into ICU

Cohort 3
• Men and non-pregnant women
• Aged 18 years of age and over
• Clinically diagnosed with circulatory compromise requiring pressor support
• Admitted to hospital as an inpatient into ICU





Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Individuals who meet the following inclusion criteria at screening will be excluded from participating in this study at the time of screening:
• Under 18 years of age
• Pregnant women
• Patients who are anti-coagulated
• Patients planned for MRI scans
• Severe tape allergy
• Major medical or psychiatric illness that would interfere with protocol adherence
• Individuals unable to read, speak, or understand English, or those for whom translation
services/certified translated documents are not available
• Any other reason that in the opinion of the investigator would prevent the subject from
completing study procedures.

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29650 0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Recruitment postcode(s) [1] 45995 0
3065 - Fitzroy

Funding & Sponsors
Funding source category [1] 321610 0
Charities/Societies/Foundations
Name [1] 321610 0
Helmsley Charitable Trust
Country [1] 321610 0
Australia
Primary sponsor type
Hospital
Name
St Vincent's Hospital Melbourne
Address
Country
Australia
Secondary sponsor category [1] 324419 0
None
Name [1] 324419 0
Address [1] 324419 0
Country [1] 324419 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320136 0
St Vincent’s Hospital Human Research Ethics Committee
Ethics committee address [1] 320136 0
Ethics committee country [1] 320136 0
Australia
Date submitted for ethics approval [1] 320136 0
21/04/2026
Approval date [1] 320136 0
11/06/2026
Ethics approval number [1] 320136 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149558 0
Prof David O'Neal
Address 149558 0
St Vincent's Hospital Melbourne, Level 4, Clinical Sciences Building, 29 Victoria Parade, Fitzroy, VIC, 3065
Country 149558 0
Australia
Phone 149558 0
+61 425731665
Fax 149558 0
Email 149558 0
Contact person for public queries
Name 149559 0
Dr Yee Wen Kong
Address 149559 0
Diabetes Technology Research Group, Level 4, Daly Wing North, 35 Victoria Parade, Fitzroy, VIC, 3065
Country 149559 0
Australia
Phone 149559 0
+61 3 9231 2757
Fax 149559 0
Email 149559 0
Contact person for scientific queries
Name 149560 0
David O'Neal
Address 149560 0
St Vincent's Hospital Melbourne, Level 4, Clinical Sciences Building, 29 Victoria Parade, Fitzroy, VIC, 3065
Country 149560 0
Australia
Phone 149560 0
+61 3 9231 2757
Fax 149560 0
Email 149560 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.